Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2026 11:38 ET | Source: Novo Nordisk A/S

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025

We are very encouraged by the promising early uptake from the US launch of Wegovy® pill, and we remain confident in our ability to drive volume growth
February 03, 2026 11:37 ET | Source: Novo Nordisk A/S

Novo Nordisk releases 2026 sales and operating profit outlook

In 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and...
February 02, 2026 10:43 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.
January 31, 2026 02:00 ET | Source: Novo Nordisk A/S

New employee representative on the Board of Directors of Novo Nordisk A/S

Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S.
January 20, 2026 08:30 ET | Source: Novo Nordisk A/S

Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes

Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
December 31, 2025 08:24 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent

Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent
December 22, 2025 17:50 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

FDA has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term
December 12, 2025 08:57 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
December 09, 2025 08:51 ET | Source: Novo Nordisk A/S

Novo Nordisk has completed its acquisition of Akero Therapeutics

Novo Nordisk and Akero Therapeutics Inc. today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed
November 25, 2025 06:24 ET | Source: Novo Nordisk A/S

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeksAmycretin demonstrated statistically significant reductions in HbA1c with up to 89.1% achieving HbA1c levels below...